Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Medizinische Hochschule Hannover
Sponsor

Medizinische Hochschule Hannover

Germany Carl-Neuberg-Strasse 1, Gross Buchholz, 30625 Hanover, Germany

About the sponsor

Research activity includes acute myeloid leukaemia with IDH1-mutated AML, myelodysplastic syndrome, and relapsed or refractory AML, alongside chronic lymphocytic leukaemia and small lymphocytic lymphoma. The portfolio also covers minimal residual disease assessment in AML and CLL.

  • Acute myeloid leukaemia
  • Myelodysplastic syndrome
  • Chronic lymphocytic leukaemia
  • Minimal residual disease

Clinical interest extends to treatment-resistant disease, remission status, and consolidation strategies in blood cancers.

About Specializations

Medizinische Hochschule Hannover runs clinical trials in conditions such as Acute myeloid leukaemia, Myelodysplastic syndrome, Liver transplant, Chronic lymphocytic leukaemia, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

9 clinical trials

Liver transplant

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Medizinische Hochschule Hannover

Acute myeloid leukaemia+3

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Medizinische Hochschule Hannover

Li-Fraumeni syndrome

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Metformin
  • Sponsor:Medizinische Hochschule Hannover

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Not yet recruiting
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Hepatitis B e antigen negative

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Hepatitis B Immunoglobulin
  • Sponsor:Medizinische Hochschule Hannover

Acute myeloid leukaemia+1

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Medizinische Hochschule Hannover

Acute myocardial infarction

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:Medizinische Hochschule Hannover

Congenital cystic kidney disease

Not recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Medizinische Hochschule Hannover

Otorhinolaryngological surgery

Not recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vsf1.01
  • Sponsor:Medizinische Hochschule Hannover

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.